Pant et al Esmaeli B, Valero V, Ahmadi MA, et al. 2001. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology, 108:994–5. Esmaeli B. 2005. Management of excessive tearing as a side effect of docetaxel. Clin Breast Cancer, 5:455–7. Hainsworth JD, Burris HA 3rd, Greco FA. 1999. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol, 26(Suppl 10):19–24. Henderson IC, Berry DA, Demetri GD, et al. 2003. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 21:976–83. Jones SE, Savin MA, Holmes FA, et al. 2006. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophos- phamide as adjuvant therapy for operable breast cancer. J Clin Oncol, 24:5381–7. Markman M. Managing taxane toxicities. 2003. Support Care Cancer, 11:144–7. Martin M, Pienkowski T, Mackey J, et al. 2005. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med, 352:2302–13. Michaud LB, Valero V, Hortobagyi G. 2000. Risks and beneﬁts of taxanes in breast and ovarian cancer. Drug Safety, 23:401–28. Piccart MJ, Klijn J, Paridaens R, et al. 1997. Corticosteroids signiﬁcantly delay the onset of docetaxel-induced ﬂuid retention: ﬁnal results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol, 15:3149–55. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353:1659–72. Piedbois P-P, Serin D, Priou F, et al. 2005. AERO-B03: A randomized phase ll trial of dose-dense, docetaxel in node-positive breast cancer. J Clin Oncol, 23(16S):Abstract 647. Ravdin PM, Burris HA 3rd, Cook G, et al. 1995. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol, 13:2879–85. Ringel I, Horwitz SB. 1991. Studies with RP 56976 (taxotere): a semisyn- thetic analogue of taxol. J Natl Cancer Inst, 83:288–91. Roché H, Fumoleau P, Spielmann M, et al. 2006. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol, 24:5664–71. Romond EH, Perez EA, Bryant J, et al. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353:1673–84. Schrijvers D, Wanders J, Dirix L, et al. 1993. Coping with toxicities of docetaxel (Taxotere). Ann Oncol, 4:610–11. Slamon D, Eiermann W, Robert N, et al. 2005. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC⇒T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC⇒TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Proc SABCS:Abstract 1. Slamon DJ, Leyland-Jones B, Shak S, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344:783–92. Spielmann M, Roché H, Delozier T, et al. 2006. Safety analysis from PACS 04-A phase lll trial comparing 6 cycles of FEC 100 with 6 cycles of ET75 for node-positive early breast cancer patients followed by sequential trastuzumab in HER2 patients: Preliminary results. J Clin Oncol, 24(18S):Abstract 632. Trudeau M, Charbonneau F, Gelmon K, et al. 2005. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol, 6:886–98. Valeria F, Ester E, Modesto D’Aprile, et al. 2001. A feasibilty study of a sequential dose-dense adjuvant regimen with epidoxorubicin fol- lowed by docetaxel followed by high-dose cyclophosphamide for early breast cancer with 4 or more lymph node metastases. Annals of Oncol, 12(4S):52. Valero V, Holmes FA, Walters RS, et al. 1995. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol, 13:2886–94. Valero V, Jones SE, Von Hoff DD, et al. 1998. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol, 16:3362–8. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. 2000. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol, 18:2733–9. Vogel CL, Mackey JR, Martin M, et al. 2004. The role of growth factor support following neutropenic events n early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophos- phamide (TAC): A sub-analysis of BCIRG 001. J Clin Oncol, 22(14S): Abstract 677. Zimmerman GC, Keeling JH, Burris HA, et al. 1995. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol, 131:202–6. Zimmerman GC, Keeling JH, Lowry M, et al. 1994. Prevention of docetaxel- induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst, 86:557–8. 424 Therapeutics and Clinical Risk Management 2008:4(2)